skip to main content

Idioma:

De-novo and acquired resistance to immune checkpoint targeting (Figure 4)

Syn, Nicholas

figshare 2017

Texto completo disponível

Citações Citado por

Enviar para

Título:
De-novo and acquired resistance to immune checkpoint targeting (Figure 4)
Autor: Syn, Nicholas
Assuntos: Allergy ; Analytical Biochemistry ; Animal Cell and Molecular Biology ; Animal Immunology ; Animal Physiology - Cell ; Animal Physiology - Systems ; Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies) ; Autoimmunity ; Bacteriology ; Basic Pharmacology ; Biochemistry and Cell Biology not elsewhere classified ; Bioinformatics ; Biological Adaptation ; Biological Engineering ; Biological Sciences not elsewhere classified ; Biological Techniques ; Biomarkers ; Biophysics ; Biotechnology ; Cancer ; Cancer Cell Biology ; Cancer Diagnosis ; Cancer Genetics ; Cancer Therapy (excl. Chemotherapy and Radiation Therapy) ; Cell and Nuclear Division ; Cell Biology ; Cell Development, Proliferation and Death ; Cell Metabolism ; Cell Physiology ; Cellular Immunology ; Cellular Interactions (incl. Adhesion, Matrix, Cell Wall) ; Cellular Nervous System ; Central Nervous System ; Chemotherapy ; Clinical Chemistry (diagnostics) ; Clinical Microbiology ; Clinical Pharmacology and Therapeutics ; Clinical Pharmacy and Pharmacy Practice ; Clinical Sciences not elsewhere classified ; Comparative Physiology ; Computational Biology ; Dental Therapeutics, Pharmacology and Toxicology ; Dentistry not elsewhere classified ; Dermatology ; Developmental Biology ; Endocrinology ; Enzymes ; Epidemiology ; Epigenetics (incl. Genome Methylation and Epigenomics) ; Evolutionary Biology ; Evolutionary Biology not elsewhere classified ; FOS: Basic medicine ; FOS: Biological sciences ; FOS: Clinical medicine ; FOS: Computer and information sciences ; FOS: Health sciences ; FOS: Medical biotechnology ; FOS: Other medical sciences ; Gastroenterology and Hepatology ; Gene Expression (incl. Microarray and other genome-wide approaches) ; Genetic Immunology ; Genetics ; Genetics not elsewhere classified ; Genome Structure and Regulation ; Genomics ; Geriatrics and Gerontology ; Haematological Tumours ; Haematology ; Health Care ; Hematology ; Humoural Immunology and Immunochemistry ; Immunogenetics (incl. Genetic Immunology) ; Immunology ; Immunology not elsewhere classified ; Infectious Agents ; Infectious Diseases ; Innate Immunity ; Medical and Health Sciences not elsewhere classified ; Medical Bacteriology ; Medical Biochemistry and Metabolomics not elsewhere classified ; Medical Biochemistry: Amino Acids and Metabolites ; Medical Biochemistry: Carbohydrates ; Medical Biochemistry: Lipids ; Medical Biochemistry: Nucleic Acids ; Medical Biochemistry: Proteins and Peptides (incl. Medical Proteomics) ; Medical Genetics (excl. Cancer Genetics) ; Medical Infection Agents (incl. Prions) ; Medical Microbiology not elsewhere classified ; Medical Physiology not elsewhere classified ; Medical Virology ; Medicine ; Metabolic Medicine ; Microbial Ecology ; Microbial Genetics ; Microbiology ; Microbiology not elsewhere classified ; Molecular Biology ; Molecular Evolution ; Molecular Targets ; Nephrology and Urology ; Neurology and Neuromuscular Diseases ; Obstetrics and Gynaecology ; Oncology and Carcinogenesis not elsewhere classified ; Oral Medicine and Pathology ; Orthopaedics ; Pathogenesis ; Pathology ; Pathology (excl. Oral Pathology) ; Pharmaceutical Sciences ; Pharmacogenomics ; Pharmacology ; Pharmacology and Pharmaceutical Sciences not elsewhere classified ; Phylogeny and Comparative Analysis ; Physiology ; Physiology not elsewhere classified ; Protein Trafficking ; Proteomics and Intermolecular Interactions (excl. Medical Proteomics) ; Quantitative Genetics (incl. Disease and Trait Mapping Genetics) ; Radiation Therapy ; Radiology and Organ Imaging ; Receptors and Membrane Biology ; Respiratory Diseases ; Rheumatology and Arthritis ; Signal Transduction ; Solid Tumours ; Stem Cells ; Structural Biology ; Structural Biology (incl. Macromolecular Modelling) ; Surgery ; Synthetic Biology ; Systems Biology ; Systems Physiology ; Toxicology ; Toxicology (incl. Clinical Toxicology) ; Tumour Immunology ; Virology
Descrição: Figure 4: Tumour microenvironment and neovasculatureTumour endothelium plays a part in engendering spatially-limited immunoresistant niches by expressing the FasL ligand, which kills effector CD8 T cells, and also byposing as a physical barrier to prevent extravasation into the tumour parenchyma. Furthermore, tolerogenic cell types and immunosuppressive molecules present inthe tumour microenvironment and metabolic competition for nutrients have been shown to induce exhaustion and inactivation of CD8 T-cell infiltrates, therebylimiting the durability of immune checkpoint inhibition. Fas=apoptosis antigen 1. FasL=ligand for FAS receptor. Treg=regulatory T cell.
Editor: figshare
Data de criação/publicação: 2017
Idioma: Inglês

Links

org

Voltar para lista de resultados

Ir para página anterior

Anterior Resultado 2 Avançar Ir para próxima página

Ir para próxima página

Realização: Logos de Redes Sociais:

Buscando em bases de dados remotas. Favor aguardar.

Buscando por
emscope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
Mostrar o que foi encontrado até o momento